Results of international trial show promise in rare, difficult to treat cancer: Results from the RADIANT-4 trial

An international team of researchers has shown that the use of the mTOR inhibitor, everolimus, can delay tumour growth among both gastrointestinal and lung neuroendocrine tumours. This is particularly important for patients with lung NETs because there is currently no approved treatment for such cases.